AntiCoagulation Versus AcetylSalicylic Acid After Transcatheter Aortic Valve Implantation
NCT05035277
Summary
ACASA-TAVI is a pragmatic randomized controlled trial assessing the value of anticoagulation therapy versus the standard antiplatelet therapy after transcatheter aortic valve implantation in patients with aortic stenosis. The trial will assess the efficacy of direct oral anticoagulation (DOAC) therapy compared to the standard single antiplatelet therapy to prevent degeneration of the valve and its safety in co-primary endpoints with blinded endpoint adjudication. The effect of DOAC therapy on hard clinical outcomes will be assessed during long-term follow-up.
Eligibility
Inclusion Criteria: * Successful trans-catheter aortic valve implantation in patients aged \>65 and \<80 years old at the time of the procedure. Exclusion Criteria: * Strict indication for anticoagulation or anti-platelet drugs * Strict contraindication for anticoagulation or anti-platelet drugs * Overt cognitive failure * Failure to obtain written informed consent * Concomitant use of inducers or inhibitors of CYP3A4 or P-glycoprotein
Conditions2
Interventions4
Related trials
- Apixaban-PK Trial: Preventing Portal Hypertension Complications in Cirrhosis — Asian Institute Of Medical Sciences
- COmparison of Bleeding Risk Between Rivaroxaban and Apixaban in Patients With Atrial Fibrillation — Ottawa Hospital Research Institute
- Comparison of the Effects of Apixaban on Thrombin Generation in Patients With de Novo Multiple Myeloma — Centre Hospitalier Universitaire de Saint Etienne
- Pharmacokinetics of Apixaban in Peritoneal Dialysis — Chinese University of Hong Kong
- Reduced-Dose Apixaban and Rivaroxaban Versus Low-Molecular-Weight Heparin in Patients With Hematologic Malignancies — Medical University of Gdansk
- Secondary Prevention of VTE in Patients With Cancer and Catheter-Related Upper Extremity Deep Vein Thrombosis — Ottawa Hospital Research Institute
- Anticoagulation in ICH Survivors for Stroke Prevention and Recovery — Yale University
- Safety in Adult Participants With Atrial Fibrillation Who Are Treated With Anticoagulation — Regeneron Pharmaceuticals
Browse More Trials
Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.
This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.
NCT05035277